Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Shares Shorted: Short Interest Up 229.2% in October

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the target of a significant increase in short interest in the month of October. As of October 30th, there was short interest totaling 9,890 shares, an increase of 229.2% from the October 15th total of 3,004 shares. Based on an average trading volume of 25,967 shares, the short-interest ratio is currently 0.4 days. Approximately 0.0% of the company’s stock are sold short.

Emmaus Life Sciences Price Performance

EMMA remained flat at $0.02 during trading on Thursday. 19,000 shares of the company traded hands, compared to its average volume of 17,983. The stock has a market capitalization of $1.54 million, a P/E ratio of -0.24 and a beta of 11.25. Emmaus Life Sciences has a 1-year low of $0.01 and a 1-year high of $0.09. The stock has a 50 day moving average of $0.05 and a 200-day moving average of $0.02.

Emmaus Life Sciences (OTCMKTS:EMMA) last announced its earnings results on Friday, August 14th. The company reported $0.02 earnings per share for the quarter. The company had revenue of $6.32 million during the quarter.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and debilitating diseases. The company’s best-known product is Endari, an oral powder formulation of L-glutamine approved in the United States to reduce the frequency of acute complications associated with sickle cell disease in adults and children aged five and older. Emmaus has focused its research and development activities on therapies for diseases with significant unmet medical needs, including hematological and other rare disorders.